Patents by Inventor Akira Kaieda
Akira Kaieda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11401264Abstract: The present invention provides a heterocyclic compound having an activity to promote the maturation of a cardiomyocyte. A compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof has an activity to promote the maturation of a cardiomyocyte, and is useful as a cardiomyocyte maturation promoter.Type: GrantFiled: March 28, 2019Date of Patent: August 2, 2022Assignee: Orizuru Therapeutics, Inc.Inventors: Yoshinori Yoshida, Kenji Miki, Akira Kaieda, Shigeru Kondo, Hiroshi Nara, Yoshinori Ikeura
-
Publication number: 20210024512Abstract: The present invention provides a heterocyclic compound having an activity to promote the maturation of a cardiomyocyte. A compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof has an activity to promote the maturation of a cardiomyocyte, and is useful as a cardiomyocyte maturation promoter.Type: ApplicationFiled: March 28, 2019Publication date: January 28, 2021Applicants: Kyoto University, Takeda Pharmaceutical Company LimitedInventors: Yoshinori YOSHIDA, Kenji MIKI, Akira KAIEDA, Shigeru KONDO, Hiroshi NARA, Yoshinori IKEURA
-
Patent number: 10406146Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of inflammatory disease and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: August 24, 2016Date of Patent: September 10, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Akira Kaieda, Naoki Ishii, Hiroshi Nara, Masato Yoshikawa, Masaki Daini
-
Patent number: 10357484Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: July 15, 2016Date of Patent: July 23, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Akira Kaieda, Masaki Daini, Hiroshi Nara, Masato Yoshikawa, Naoki Ishii, Masashi Toyofuku, Kousuke Hidaka
-
Patent number: 10308643Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: July 15, 2016Date of Patent: June 4, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Akira Kaieda, Masashi Toyofuku, Masaki Daini, Hiroshi Nara, Masato Yoshikawa, Naoki Ishii, Kousuke Hidaka
-
Publication number: 20190008836Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: July 15, 2016Publication date: January 10, 2019Inventors: Akira KAIEDA, Masaki DAINI, Hiroshi NARA, Masato YOSHIKAWA, Naoki ISHII, Masashi TOYOFUKU, Kousuke HIDAKA
-
Patent number: 10081624Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: August 25, 2015Date of Patent: September 25, 2018Assignee: Takeda Pharmaceutical Company LimitedInventors: Akira Kaieda, Naoki Ishii, Hiroshi Nara, Masato Yoshikawa, Masaki Daini, Masashi Toyofuku, Kousuke Hidaka
-
Publication number: 20180263967Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of inflammatory disease and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: August 24, 2016Publication date: September 20, 2018Inventors: Akira KAIEDA, Naoki ISHII, Hiroshi NARA, Masato YOSHIKAWA, Masaki DAINI
-
Publication number: 20180222896Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: August 25, 2015Publication date: August 9, 2018Applicant: Takeda Pharmaceutical Company LimitedInventors: Akira Kaieda, Noaki Ishii, Hiroshi Nara, Masato Yoshikawa, Masaki Daini, Mashashi Toyofuku, Kousuke Hidaka
-
Publication number: 20170015655Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: July 15, 2016Publication date: January 19, 2017Inventors: Akira KAIEDA, Masashi TOYOFUKU, Masaki DAINI, Hiroshi NARA, Masato YOSHIKAWA, Naoki ISHII, Kousuke HIDAKA
-
Publication number: 20160251352Abstract: The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: May 6, 2016Publication date: September 1, 2016Inventors: Hiroshi NARA, Masaki DAINI, Akira KAIEDA, Taku KAMEI, Toshihiro IMAEDA, Fumiaki KIKUCHI
-
Patent number: 9371320Abstract: The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: May 31, 2013Date of Patent: June 21, 2016Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Hiroshi Nara, Masaki Daini, Akira Kaieda, Toshihiro Imaeda, Fumiaki Kikuchi
-
Publication number: 20150141406Abstract: The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: May 31, 2013Publication date: May 21, 2015Inventors: Hiroshi Nara, Masaki Daini, Akira Kaieda, Taku Kamei, Toshihiro Imaeda, Fumiaki Kikuchi
-
Patent number: 7915267Abstract: The present invention provides a novel amide compound represented by the following formula, which has a matrix metalloproteinase inhibitory activity and is useful as a pharmaceutical agent. wherein each symbol is as defined in the specification.Type: GrantFiled: October 27, 2006Date of Patent: March 29, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Hiroshi Nara, Akira Kaieda, Kenjiro Sato, Jun Terauchi
-
Publication number: 20090137603Abstract: The present invention provides a novel amide compound represented by the following formula, which has a matrix metalloproteinase inhibitory activity and is useful as a pharmaceutical agent. wherein each symbol is as defined in the specification.Type: ApplicationFiled: October 27, 2006Publication date: May 28, 2009Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Hiroshi Nara, Akira Kaieda, Kenjiro Sato, Jun Terauchi